{"filings":[{"id":1303758,"accession_number":"0001193125-26-285424","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-06-26T20:01:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio principal accounting officer Robert Lally resigns, effective July 22, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Lally, SVP of Finance and Operations and principal accounting officer, resigned effective July 22, 2026.","Resignation was not due to any disagreement with the company.","Company plans to conduct a search for Mr. Lally's replacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1111037,"accession_number":"0001193125-26-274139","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-06-17T20:05:45+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve amendment to 2025 Equity Incentive Plan, adding 850,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment increases authorized shares by 850,000; includes convertible preferred and pre-funded warrants in annual auto-increase calculation.","Holders elect David P. Bonita, M.D. and Joseph P. Slattery as Class II directors for term until 2029.","Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026.","All proposals approved with over 84% of votes cast in favor for each (excluding broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96031,"accession_number":"0001193125-26-211935","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImageneBio Q1 net loss $10.6M; cash $117.2M, raised $30M in April private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.6M for Q1 2026, vs $9.1M in Q1 2025; R&D $6.0M, G&A $6.1M.","Cash of $117.2M as of March 31; April private placement raised $30M, extending runway into Q1 2028.","Phase 2b ADAPTIVE trial in AD advancing under amended protocol; topline data anticipated Q4 2027.","Plan to initiate Phase 2 in alopecia areata in 2026; initial data expected 2028, based on proof-of-concept."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96030,"accession_number":"0001193125-26-151942","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"ImageneBio raises ~$30M via pre-funded warrants to fund atopic dermatitis and alopecia areata programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$30M from sale of pre-funded warrants for 5.77M shares at $5.199 each.","Closing expected April 14, 2026; warrants exercisable at $0.001, no expiration.","Proceeds to fund late-phase development in atopic dermatitis and expand IMG-007 into alopecia areata.","Registration rights agreement requires filing by early August 2026; cash penalties for delays.","Beneficial ownership limitation set at 19.99% per investor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109528,"accession_number":"0001193125-26-110945","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio PAO Erin Butler to depart; Bob Lally named as successor","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mutual separation of Erin Butler, SVP Finance & Administration and Principal Accounting Officer, effective March 20, 2026.","Bob Lally, SVP Finance & Operations, appointed as Principal Accounting Officer effective March 20, 2026.","Butler to receive severance per existing Severance Rights Agreement dated October 21, 2024.","Lally previously served at Ikena Oncology (SVP Finance & Operations) and Prevail Therapeutics (VP Finance, COO)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109527,"accession_number":"0001193125-26-099422","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.","Net loss Q4 2025: $6.9M vs $4.8M Q4 2024, driven by post-merger operating costs and transaction expenses.","Phase 2b ADAPTIVE trial (IMG-007 in atopic dermatitis) enrolling on schedule; blinded safety review found no pyrexia/chills/ulcers/malignancies.","Appointed Dr. Ben Porter-Brown as CMO in Feb 2026; also added CEO, CSO, CTO, and an independent director during 2025.","Submitted protocol amendment to expand dosing regimens, evaluate loading doses, and test patient-friendly intervals in ADAPTIVE."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109526,"accession_number":"0001193125-26-054684","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2026-02-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio board member Steven Hui Wang resigns effective Feb 12, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Steven Hui Wang resigned from the Board of Directors on February 12, 2026, effective immediately.","Resignation was not due to any disagreement with the Company's operations, policies, or strategy.","No replacement has been announced; board size reduces accordingly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126055,"accession_number":"0001193125-25-324798","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Imagenebio CMO Yufang Lu resigns effective Dec 31, 2025; search underway","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Yufang Lu, M.D., Ph.D., Chief Medical Officer, resigned effective December 31, 2025.","Resignation not due to any disagreement with company operations, policies, or practices.","Company conducting search for replacement; Lu expected to provide transition advisory services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126054,"accession_number":"0001193125-25-286984","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ImageneBio updates corporate presentation; no new material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company released updated corporate presentation dated November 19, 2025.","Presentation posted on company website for investor meetings.","No financial or operational updates were provided in the filing excerpt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126053,"accession_number":"0001193125-25-275910","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ImageneBio reports Q3 net loss of $24.8M; advances Phase 2b AD trial with protocol amendment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $142.6M as of Sep 30, 2025; net loss $24.8M for Q3 2025 vs $3.2M in Q3 2024; R&D $15.6M, G&A $11.0M.","Phase 2b ADAPTIVE trial protocol amendment to expand dosing regimens; topline data expected in 2027; enrollment ongoing.","New alopecia areata data (Phase 1b/2a) and atopic dermatitis data to be presented at ISDS Nov 12-15, 2025.","Completed reverse merger with Ikena Oncology and $75M private placement; new CEO Kristin Yarema, CSO Kurinji Pandiyan, CTO Renuka Sivendran, and independent director Joe Slattery."],"consensus_eps_estimate":null,"consensus_eps_actual":-9.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":800000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126052,"accession_number":"0001193125-25-266889","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio appoints Joseph P. Slattery to Board and Audit Committee chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 6 to 7; Slattery appointed director effective Nov 1, 2025.","Slattery to serve as Audit Committee Chair effective Nov 18, 2025.","Standard indemnification agreement entered into with Slattery."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126051,"accession_number":"0001193125-25-254697","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Imagenebio terminates Miragene transition agreement; extends partial services for 6 months at $200K","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected not to auto-renew transition services agreement with Miragene Inc. dated July 25, 2025.","Extended term six months for subset of services (chemistry, manufacturing, controls, translational sciences).","Total fees for Miragene Extension Services: $200,000.","End of initial term triggers partial extension; full termination after extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126050,"accession_number":"0001193125-25-245823","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"ImageneBio CEO Kristin Yarema appointed interim principal financial officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed CEO Kristin Yarema as interim CFO effective Oct 21, 2025.","Yarema previously served as CEO; biographical info referenced from Sept 2025 S-1 filing.","No reason for the change or prior CFO departure disclosed in the filing.","The appointment is effective immediately; Yarema continues as CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126049,"accession_number":"0001193125-25-237161","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Jotin Marango resigns effective Oct 20; search for replacement begun","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jotin Marango, M.D., Ph.D., resigned effective October 20, 2025.","Resignation not due to any disagreement with the company.","Company will conduct a search for Marango's replacement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142782,"accession_number":"0001193125-25-179093","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K/A","filed_at":"2025-08-12T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"ImageneBio files Inmagene pre-merger financials: $13.7M loss, going concern, $6M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Inmagene net loss of $7.6M in Q2 2025 and $13.7M in first half 2025; accumulated deficit $197.5M.","Cash and equivalents $6.0M at June 30, 2025; operating cash burn $19.1M in first half 2025.","Management states substantial doubt about continuing as a going concern; cash insufficient for next 12 months.","Term loan of $22.9M (6% interest, secured by IMG-007) automatically forgiven upon merger close July 25, 2025.","Ikena concurrent financing of $75M contributed to fund IMG-007 development after merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142785,"accession_number":"0001193125-25-173626","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"ImageneBio dismisses EY, appoints PwC as auditor effective Aug 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed Ernst & Young LLP as independent auditor effective August 2, 2025.","No disagreements or reportable events occurred during EY's audit periods (2024, 2023 and interim).","PricewaterhouseCoopers LLP appointed as new auditor for fiscal year ending Dec 31, 2025.","PwC previously served as auditor of Inmagene Biopharmaceuticals prior to merger with ImageneBio.","EY's audit reports for 2024 and 2023 were unqualified, with no adverse opinions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142784,"accession_number":"0001193125-25-171747","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-08-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"ImageneBio adopts 2025 Inducement Plan, reserves 589,585 shares for new employee equity grants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 2025 Inducement Plan on July 28, 2025, reserving 589,585 shares for grants to new employees.","Plan used exclusively for inducement grants to individuals not previously employees or directors, per Nasdaq Listing Rule 5635(c)(4).","Terms substantially similar to stockholder-approved 2025 Equity Incentive Plan; no stockholder approval required.","Award types: Nonstatutory Stock Options and RSUs; vesting and exercise terms standard."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142783,"accession_number":"0001193125-25-167089","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.01","1.01","3.02","9.01","5.02","3.03","5.01","5.03","5.06","7.01"],"status":"ready","headline":"Ikena completes reverse merger with Inmagene, becomes ImageneBio; focuses on IMG-007 for atopic dermatitis","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed July 25: Ikena acquired Inmagene, name changed to ImageneBio, ticker changes to IMA on Nasdaq Capital Market.","Reverse stock split 1-for-12; post-merger shares ~11.2M; pre-merger Inmagene holders get ~43.5% of combined co.","Only clinical asset: IMG-007 (anti-OX40 mAb) in Phase 2b ADAPTIVE trial for atopic dermatitis; non-OX40 assets divested.","CVR agreements provide contingent payments to legacy Ikena and Inmagene shareholders from future asset sales.","PIPE investors own ~21.5%; Hutchmed license has up to $92.5M in development/regulatory milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142781,"accession_number":"0001193125-25-165170","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ikena Oncology completes merger with Inmagene, becomes ImageneBio, raises $75M private placement","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed July 25, 2025; combined company renamed ImageneBio, Inc., trading on Nasdaq under IMA starting July 28.","Concurrent $75.0M private placement from investors including Deep Track Capital, Foresite Capital, RTW Investments, and existing Ikena investors.","Legacy Inmagene holders own ~55% (pre-financing) or ~43.1% (post-financing); Ikena holders own ~45% (pre) or ~35.3% (post); new investors own ~21.6%.","ImageneBio to advance IMG-007 Phase 2b trial in moderate-to-severe atopic dermatitis; topline readout expected Q4 2026.","Kristin Yarema, Ph.D. appointed CEO; Ikena implemented a 1-for-12 reverse stock split prior to closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142780,"accession_number":"0001193125-25-163990","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ikena Oncology to effect 1-for-12 reverse stock split, rename to ImageneBio, ticker IMA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-12 reverse stock split effective July 28, 2025; shares outstanding drop from ~48.2M to ~4M.","Company will rename ImageneBio, Inc., trade under ticker \"IMA\" on Nasdaq, new CUSIP 45175G207.","No fractional shares; cash paid based on July 24 closing price multiplied by fractional share.","Exercise prices and shares underlying equity awards will be proportionally adjusted; par value unchanged.","Stockholders in book-entry or brokerage accounts need no action; beneficial holders contact broker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142779,"accession_number":"0001193125-25-162584","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ikena Oncology declares one-time CVR dividend; record date July 24, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved one contingent value right (CVR) per share of IKNA common stock.","Shareholders of record as of July 24, 2025 will receive one CVR per share.","CVRs entitle holders to net proceeds from sales of pre-Merger assets, including IK-595.","Proceeds subject to deductions for taxes, expenses, and wind-down costs.","No assurance any CVR payments will be received; CVRs may have no value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142778,"accession_number":"0001193125-25-159910","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ikena Oncology amends executive’s equity vesting terms tied to pending Inmagene merger","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective July 15, 2025, Ikena Oncology amended employment agreement with Dr. Jotin Marango, an executive officer.","Amendment provides for full acceleration of time-based equity awards if termination without cause or resignation during change in control period.","Change in control period began March 18, 2025 (initial S-4 filing for merger with Inmagene) and ends 12 months post-merger.","Accelerated vesting effective later of termination date or change in control; forfeiture of unvested portions delayed until that date.","Contemplated merger with Inmagene Biopharmaceutics was announced December 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142777,"accession_number":"0001193125-25-159400","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Ikena stockholders approve Inmagene merger; 1:12 reverse split; combined co. to trade as IMA","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All 7 proposals approved including merger issuance of IKNA shares >20% and reverse split.","1-for-12 reverse stock split to reduce outstanding shares from ~48.2M to ~4M.","Merger and concurrent financing expected to close around end of July 2025.","Combined company will be ImageneBio, Inc., trading on Nasdaq under ticker IMA.","New CUSIP for post-split common stock: 45175G 207."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142776,"accession_number":"0001193125-25-157867","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ISS and Glass Lewis recommend Ikena stockholders vote FOR Inmagene merger","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Institutional Shareholder Services (ISS) and Glass Lewis recommend voting FOR share issuance related to merger with Inmagene.","Ikena's Annual Meeting is July 15, 2025; record date was May 22, 2025.","Inmagene's lead candidate is IMG-007, a nondepleting anti-OX40 mAb for immune & inflammatory diseases.","CEO Mark Manfredi cited IMG-007's potential to build shareholder value in I&I space.","Proxy includes seven proposals; all votes are important for merger approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142775,"accession_number":"0001193125-25-154016","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Inmagene doses first patient in Phase 2b ADAPTIVE trial of IMG-007 for atopic dermatitis; data expected Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IMG-007 targets OX40 receptor with silenced ADCC to minimize safety risks and extended half-life for convenient dosing.","ADAPTIVE trial is a global Phase 2b enrolling ~220 patients across three IMG-007 dose arms and placebo.","Primary endpoint: mean percentage change from baseline in EASI score at Week 20.","Topline results from the Phase 2b trial are expected in the fourth quarter of 2026.","Dose-finding study designed to guide optimal dosing for future Phase 3 trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195751,"accession_number":"0001193125-24-283722","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["1.01","3.02","5.01","5.02","7.01","9.01"],"status":"ready","headline":"Ikena Oncology merges with Inmagene; Inmagene shareholders to own 55.6% of combined co.","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pre-PIPE, Inmagene shareholders own ~55.6%, Ikena ~44.4% of combined company.","PIPE financing of $75M from accredited investors, closing simultaneously with merger.","Loan agreement: Ikena to lend Inmagene up to $22.5M (initial $7.5M) secured by IMG-007 asset.","Ikena stockholders to receive CVRs for potential proceeds from pre-merger assets (e.g., IK-595).","Combined company board: 7 members, 3 from Inmagene, 2 from Ikena, 1 mutual, 1 from PIPE lead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212021,"accession_number":"0001193125-24-178568","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ikena Oncology appoints Jotin Marango as COO; grants 400K option tied to strategic transaction","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jotin Marango appointed COO effective July 15, 2024, in addition to his roles as CFO and Head of Corporate Development.","Salary increased to $470,000 per year.","Granted option to purchase 400,000 shares vesting upon consummation of a strategic transaction.","Marango previously served as CFO since April 2022; prior roles at Aptose Biosciences and Roth Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230863,"accession_number":"0001193125-24-158321","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ikena Oncology shareholders elect directors and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Owen Hughes elected as Class III director with 22,250,184 votes for, 4,967,774 withheld.","Mark Manfredi elected as Class III director with 24,738,833 votes for, 2,479,125 withheld.","Ernst & Young ratified as auditor for FY2024 with 34,421,661 for, 31,819 against, 11,827 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230862,"accession_number":"0001193125-24-148112","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["2.05","7.01","8.01","9.01"],"status":"ready","headline":"Ikena Oncology discontinues IK-930, cuts workforce 53%, explores strategic options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued IK-930 (TEAD1 inhibitor) clinical development; winddown activities began.","Reducing workforce by ~53% (18 employees); expected ~16 FTE remaining; cash costs ~$1.2M in Q2 2024.","Continuing IK-595 (MEK-RAF glue) Phase 1; >80% pERK inhibition at 4h, >60% at 24h; dose escalation ongoing.","Cash, equivalents and marketable securities $157.3M as of March 31, 2024.","Board authorized exploration of strategic alternatives including acquisition, merger, sale, or partnership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249249,"accession_number":"0001193125-24-041504","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2024-02-21T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Ikena Oncology appoints Caroline Germa as CMO; Sergio Santillana resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sergio Santillana resigns as CMO effective Feb 29, 2024; will consult through Dec 31, 2024 at $500/hour.","Caroline Germa, M.D., appointed CMO effective Feb 29, 2024; brings 25+ years pharma experience.","Dr. Germa previously EVP & CMO at Transcenta, senior roles at AstraZeneca, BMS, Novartis.","Focus on advancing IK-930 (Hippo pathway) and IK-595 (RAS/RAF mutant cancers) Phase I programs.","Company on track for clinical update in second half of 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249248,"accession_number":"0001193125-24-010227","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["2.02","2.05","7.01","8.01","9.01"],"status":"ready","headline":"Ikena Oncology cuts workforce 35%, focuses on IK-930/595; BMS declines opt-in on two programs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~35% (approx. 20 employees) to focus on clinical programs IK-930 and IK-595.","Cash, cash equivalents and marketable securities ~$175M as of Dec 31, 2023 (unaudited); runway extended into 2H 2026.","Bristol Myers Squibb declined opt-in for IK-175 program; also did not opt-in for IK-412; full rights returned to Ikena.","IK-930 optimized formulation now in clinic; clinical data update planned for 2H 2024.","IK-595 first cohort dosed and cleared safety evaluation window; enrollment in RAS/RAF mutant patients ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266733,"accession_number":"0000950170-23-061519","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Ikena reports Q3 cash $196.9M, IK-930 shows stable disease in all 7 EHE patients","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Q3 2023 cash, cash equivalents and marketable securities of $196.9M; runway into 2026.","IK-930 dose escalation: 26 patients treated; 7/7 EHE patients achieved stable disease, 3 with tumor shrinkage.","Treatment-related proteinuria in 3/26 patients, all grade 1-2, no dose reductions or interruptions.","IK-595 clinical trial expected to initiate by end of 2023; IK-930 data update planned for H2 2024.","Collaboration revenue $1.2M vs $6.4M YoY; R&D expenses $14.7M vs $18.9M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":266732,"accession_number":"0001140361-23-047880","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders approve stock issuance on conversion of Series A Preferred for Pionyr acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on October 11, 2023; 37,464,898 shares outstanding.","Proposal 1 (stock issuance on conversion of Series A Preferred) approved: 25,681,604 for, 12,086 against, 1,156 abstain.","1,647,531 shares excluded from Nasdaq vote but counted under Delaware law.","Proposal 2 (adjournment if needed) approved: 26,947,409 for, 394,239 against, 729 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283980,"accession_number":"0001193125-23-204493","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2023-08-07T23:59:59+00:00","items":["1.01","5.03","2.01","3.02","1.02","7.01","9.01"],"status":"ready","headline":"Ikena Oncology acquires Pionyr in all-stock deal, receives ~$43M net cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ikena issued 1.8M common shares and 4.2M Series A convertible preferred shares at $7.15/share for all of Pionyr.","Pionyr contributed ~$43M net cash; Ikena to use funds to accelerate IK-930 and IK-595 clinical programs.","Pionyr shareholders (including Gilead Sciences) hold ~12% of Ikena post-deal; management and board unchanged.","CVRs grant Pionyr holders 50% of net proceeds from any monetization of Pionyr legacy assets within two years.","Ikena expects initial IK-930 clinical data in 2023 and IK-595 IND filing later in 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303590,"accession_number":"0001193125-23-180591","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ikena Oncology self-reports Nasdaq rule violation; remediated via share repurchase","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Issued 6,110,000 shares at $6.55 in May 2023 offering, inadvertently exceeding 20% threshold of pre-transaction voting shares.","Repurchased 97,500 shares from an investor to remediate the excess issuance and self-reported to Nasdaq.","Nasdaq determined compliance with Listing Rule 5635(d) is regained; matter closed with no effect on listing of IKNA common stock.","Company remains listed on The Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303589,"accession_number":"0001193125-23-164481","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ikena Oncology shareholders elect three Class II directors, ratify E&Y as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["David Bonita (16.5M for, 7.6M against, 2.3M broker non-votes) elected to three-year term.","Jean-François Formela (20.8M for, 3.3M against) and Richard Wooster (20.8M for, 3.3M against) also elected.","Ernst & Young LLP ratified as independent auditor for FY2023 with 26.4M for, 9k against, 1.3k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303588,"accession_number":"0001193125-23-144274","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Ikena raises ~$40M in equity offering; Q1 cash $137.8M; runway to 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 6.11M shares at $6.55/share for gross proceeds of ~$40M; closing expected May 17, 2023.","Cash, equivalents and marketable securities $137.8M at March 31, 2023; offering proceeds extend cash runway into 2026.","Q1 collaboration revenue $5.3M (up from $3.4M YoY); R&D expense $15.6M; G&A $5.3M.","IK-930 initial monotherapy data expected 4Q 2023; IK-595 IND filing planned 2H 2023; IK-175 Fast Track designation in March."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":303587,"accession_number":"0001193125-23-103005","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ikena presents preclinical data for IK-930 with TEAD1 selectivity and wider therapeutic window vs panTEAD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IK-930 selectively inhibits TEAD1 with equivalent antitumor activity to panTEAD inhibitors but no renal toxicity in monkeys at any tested dose.","Average urinary protein-to-creatinine ratios and histopathology predicted a therapeutic index <1 for panTEAD vs broad window for IK-930.","IK-930 plus osimertinib delayed emergence of drug-tolerant persister cells in preclinical EGFR-mutant NSCLC models.","Phase 1 monotherapy dose escalation ongoing; initial monotherapy clinical data expected in 2H 2023.","Cash >$155M as of filing; runway into 2025; partnered IK-175 with BMS potentially $50M opt-in fees by early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341302,"accession_number":"0001193125-22-308371","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ikena Oncology appoints Owen Hughes as Board Chair; Ron Renaud resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Owen Hughes appointed to Board and as Chairman, effective Dec 15, 2022; fills vacancy from board expansion then reduction.","Ron Renaud resigned as Chairman and Board member to focus on role as Managing Director at Bain Capital Life Sciences; no dispute.","Hughes also named Chair of Audit Committee and member of Compensation Committee; designated audit committee financial expert.","Hughes is CEO of Sail Bio and Co-Founder of Cullinan Oncology; brings public company board experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341301,"accession_number":"0001193125-22-292953","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-11-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ikena Oncology nominates IK-595 as first RAS pathway candidate; IND targeted H2 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IK-595: MEK-RAF complex inhibitor traps MEK & RAF in inactive complex, aims to avoid resistance.","Discontinuing IK-007 (EP4 antagonist) internal development; exploring strategic alternatives.","Cash runway extended into 2025; does not include potential IK-175 opt-in fees from BMS.","IK-930 TEAD inhibitor monotherapy initial clinical data expected H2 2023; osimertinib combo starts H1 2023.","Preclinical differentiation data for IK-595 planned for H1 2023; RAS pathway implicated in >500K US cancer cases/yr."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":341300,"accession_number":"0001193125-22-282059","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Ikena Oncology reports initial IK-175 clinical data: 20% ORR in combination with nivolumab in urothelial carcinoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IK-175 combo with nivolumab: 20% ORR, 40% DCR in heavily pretreated urothelial carcinoma patients who progressed on checkpoint inhibitors.","Monotherapy: 10% ORR, 20% DCR; one confirmed partial response with duration of response 14.9 months and ongoing.","Dose escalation in solid tumors: prolonged stable disease up to >19 months; MTD not reached; 1200mg selected as expansion dose.","Well tolerated with low-grade rash, nausea (monotherapy) and fatigue, dysgeusia (combo); only 2 serious adverse events.","Program in collaboration with Bristol Myers Squibb; opt-in decision eligible through early 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377082,"accession_number":"0001193125-22-171517","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ikena Oncology shareholders elect three Class I directors and ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Iain D. Dukes (23.9M for), Maria Koehler (24.6M for), Otello Stampacchia (23.3M for) to 3-year terms.","Ratified Ernst & Young as independent auditor for FY 2022 with 28.5M votes for, 1,095 against.","Meeting held June 9, 2022; all stockholder proposals passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377081,"accession_number":"0001193125-22-103598","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-04-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ikena Oncology appoints Jotin Marango as CFO and Head of Corporate Development","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Marango will assume CFO role effective April 25, 2022, succeeding interim CFO Mark Manfredi.","Base salary of $425,000; annual bonus target of 40% of base salary.","Granted option to purchase 397,199 shares, vesting 25% on one-year anniversary and rest over 36 months.","Dr. Marango previously served as SVP, CFO and CBO at Aptose Biosciences.","Severance benefits include lump-sum payments and accelerated vesting upon qualifying termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377080,"accession_number":"0001193125-22-096765","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-04-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ikena Oncology advances IK-175 combination cohort to stage two in Phase 1b trial for urothelial carcinoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IK-175 (AHR antagonist) Phase 1b trial (NCT04200963) combination with nivolumab expansion cohort advanced to stage two in April 2022.","Patients are advanced/metastatic urothelial carcinoma progressed after multiple prior therapies including checkpoint inhibitors.","Simon two-stage design requires predefined ORR threshold (RECIST 1.1) to be met in stage one before advancing to stage two.","Monotherapy expansion cohort had previously advanced to stage two in September 2021.","Initial clinical data from the trial expected to be submitted to an oncology conference in H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395446,"accession_number":"0001193125-22-052216","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ikena Oncology appoints Francisco Olivera as acting Principal Accounting Officer (Feb 18, 2022)","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment made effective February 18, 2022, on an interim basis while a formal CFO search is conducted.","Olivera currently serves as VP of Finance, joined the company in 2019, and has over a decade of biotech experience.","He played a key role in the IPO, Series B financing, and acquisition of Amplify Medicines.","No arrangements or understandings exist with any other person regarding the appointment; no related party transactions reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395445,"accession_number":"0001193125-22-020673","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-01-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ikena Oncology COO & EVP of Finance Douglas Carlson resigns; interim PAA named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Douglas R. Carlson resigns as COO and EVP of Finance, effective Feb 18, 2022, to pursue other opportunities.","Francisco Oliveira, Head of Finance and Administration since 2019, named interim Principal Accounting Officer.","Oliveira will report to CEO Mark Manfredi while a formal search for a new CFO is conducted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":395444,"accession_number":"0001193125-22-017680","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2022-01-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ikena Oncology appoints Richard Wooster to board of directors; board increases to 8","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Richard Wooster, Ph.D., appointed to fill new vacancy, effective Jan. 21, 2022; board expands from 7 to 8.","Wooster qualifies as independent director; receives option for 29,200 shares vesting over 3 years.","He brings 30+ years oncology drug discovery experience; discovered BRCA2 gene, co-discovered BRAF mutations.","Most recently CSO at Translate Bio (acquired by Sanofi 2021); previously VP at GSK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":414173,"accession_number":"0001193125-21-326102","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ikena Oncology updates corporate presentation; no specific new data in filing body","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company updated its corporate presentation on Nov 10, 2021, furnished as Exhibit 99.1.","Presentation will be posted on the investor relations section of Ikena's website.","No financial or pipeline specifics are disclosed in the 8-K text itself."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":432464,"accession_number":"0001564590-21-043726","cik":1835579,"company_name":"ImageneBio, Inc.","ticker":"IMA","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ikena Oncology Q2 2021 net loss $12.7M; cash $264M, IK-412 IND delayed by supply","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and cash equivalents $264.0M as of June 30, 2021; expected to fund operations through 2023.","Net loss $12.7M in Q2 2021 vs $5.0M in Q2 2020; R&D expense $11.4M vs $6.3M.","IK-930 IND submission on track for end of 2021; preclinical data at EORTC-NCI-AACR conference.","IK-175 monotherapy expansion cohort enrolling additional bladder cancer patients; clinical data planned in 2022.","IK-412 IND submission delayed due to shortage of a component required for COVID-19 vaccines."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":69559991.17200674,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}